scholarly journals Changes of lipoxin levels during pregnancy and the monthly-cycle, condition the normal course of pregnancy or pathology

2020 ◽  
Vol 69 (9) ◽  
pp. 869-881
Author(s):  
Małgorzata Szczuko ◽  
Joanna Palma ◽  
Justyna Kikut ◽  
Natalia Komorniak ◽  
Maciej Ziętek
Keyword(s):  
Menstrual Cycle ◽  
Fetal Growth ◽  
Embryo Implantation ◽  
Donor Cell ◽  
Normal Pregnancy ◽  
Arachidonic Acid Metabolite ◽  
Lipoxin A4 ◽  
Vessel Remodeling ◽  
Study Results ◽  
Pregnancy And Delivery

Abstract Objective and Design The purpose of the review was to gather information on the role and possibilities of using lipoxin in the treatment of infertility and maintaining a normal pregnancy. Ovulation, menstruation, embryo implantation, and childbirth are reactions representing short-term inflammatory events involving lipoxin activities. Lipoxin A4 (LXA4) is an arachidonic acid metabolite, and in cooperation with its positional isomer lipoxin B4 (LXB4), it is a major lipoxin in mammals. Biosynthesis process occurs in two stages: in the first step, the donor cell releases the eicosanoid intermediate; secondarily, the acceptor cell gets and converts the intermediate product into LXA4 (leukocyte/platelet interaction). Results Generating lipoxin synthesis may also be triggered by salicylic acid, which acetylates cyclooxygenase-2. Lipoxin A4 and its analogues are considered as specialized pro-resolving mediators. LXA4 is an important component for a proper menstrual cycle, embryo implantation, pregnancy, and delivery. Its level in the luteal phase is high, while in the follicular phase, it decreases, which coincides with an increase in estradiol concentration with which it competes for the receptor. LXA4 inhibits the progression of endometriosis. However, during the peri-implantation period, before pregnancy is confirmed clinically, high levels of LXA4 can contribute to early pregnancy loss and may cause miscarriage. After implantation, insufficient LXA4 levels contribute to incorrect maternal vessel remodeling; decreased, shallow trophoblastic invasion; and the immuno-energetic abnormality of the placenta, which negatively affects fetal growth and the maintenance of pregnancy. Moreover, the level of LXA4 increases in the final stages of pregnancy, allowing vessel remodeling and placental separation. Methods The review evaluates the literature published in the PubMed and Embase database up to 31 December 2019. The passwords were checked on terms: lipoxin and pregnancy with combined endometriosis, menstrual cycle, implantation, pre-eclampsia, fetal growth restriction, and preterm labor. Conclusions Although no human studies have been performed so far, the cell and animal model study results suggest that LXA4 will be used in obstetrics and gynecology soon.

scholarly journals Management of myelofibrosis during pregnancy: A case report

2015 ◽  
Vol 72 (4) ◽  
pp. 383-385 ◽  
Author(s):  
Radmila Zivkovic ◽  
Olivera Markovic ◽  
Dragomir Marisavljevic ◽  
Tatjana Terzic ◽  
Ljiljana Tukic
Keyword(s):  
Case Report ◽  
Myeloproliferative Neoplasm ◽  
Primary Myelofibrosis ◽  
Normal Pregnancy ◽  
Hematologic Malignancies ◽  
Low Molecular Weight ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Pregnancy And Delivery ◽  
Normal Baby

Introduction. Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm that occurs most commonly in the decade six of life and it is very rare in the young persons. Case report. We reported a 28-year-old female patient with primary myelofibrosis who had a normal pregnancy and delivery in the week 40 of pregnancy without any complications. Two years before the diagnosis of PMF she had normal pregnancy. The patient was treated with interferon-alpha and low dose aspirin during the whole pregnancy and with low-molecular-weight heparin a week before delivery and 6 weeks after. The patient had no complications during pregnancy. She delivered in term with healthy, normal baby weight. Conclusion. Decision about treatment strategy of pregnancy associated hematologic malignancies should be made for each patient individually.

scholarly journals Ulipristal Acetate in Myomectomy Optimization in an Infertile Patient with Giant Myomas

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Elena de la Fuente ◽  
María Dolores Borrás ◽  
Miriam Rubio ◽  
Nuria Abril
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Normal Pregnancy ◽  
Uterine Wall ◽  
Surgical Removal ◽  
Preoperative Treatment ◽  
Ulipristal Acetate ◽  
Infertile Patient ◽  
Beneficial Effects ◽  
Pregnancy And Delivery

The use of ulipristal acetate (UPA) has been recently introduced in the treatment of uterine leiomyomas. This drug has proven useful to control menometrorrhagia and to reduce myoma size. In the case presented here, we show the benefits of UPA treatment in facilitating surgical removal of giant myomas in an infertile patient. In addition to myoma reduction and a better control of preoperative bleeding, the treatment with UPA reduced the duration and complexity of the surgery, as well as the area of uterine wall involved and the resulting scar. No side effects were observed and the patient became pregnant 6 months after the surgery and had a normal pregnancy and delivery. This case report shows the beneficial effects of UPA in the preoperative treatment of myomas which affect uterus function.

NORMAL PREGNANCY AND DELIVERY WITH IMPLANTED CARDIAC PACEMAKER

1969 ◽  
Vol 24 (11) ◽  
pp. 1358-1359
Author(s):  
PAUL H. GERST ◽  
SYLVIA P. GRIFFITHS ◽  
PAUL J. POPPERS ◽  
RAYMOND M. MCCAFFREY ◽  
W. DUANE TODD
Keyword(s):  
Cardiac Pacemaker ◽  
Normal Pregnancy ◽  
Pregnancy And Delivery

DETERMINATION OF PLASMA OESTRIOL IN NORMAL PREGNANCY AND LABOUR USING GAS-LIQUID CHROMATOGRAPHY

1971 ◽  
Vol 51 (3) ◽  
pp. 447-454 ◽  
Author(s):  
W. COOPER ◽  
M. G. COYLE ◽  
J. A. MILLS
Keyword(s):  
Gas Chromatography ◽  
Liquid Chromatography ◽  
Quantitative Determination ◽  
Internal Standard ◽  
Normal Pregnancy ◽  
Gas Liquid Chromatography ◽  
Chemical Purification ◽  
Peripheral Plasma ◽  
Pregnancy And Delivery

SUMMARY A method is described for estimating oestriol in 2–10 ml samples of human pregnancy peripheral plasma. It incorporates acid hydrolysis, chemical purification, methylation, chromatography on alumina columns, formation of a derivative and quantitative determination by gas chromatography. A radioactive internal standard was added to correct for procedural losses. Plasma oestriol determinations in five normal patients throughout pregnancy and delivery are reported.

scholarly journals The imbalance of metal-containing proteins and free metal ions in the amniotic fluid during fetal growth

2016 ◽  
Vol 62 (1) ◽  
pp. 69-72 ◽  
Author(s):  
T.N. Pogorelova ◽  
V.A. Linde ◽  
V.O. Gunko ◽  
S.N. Selyutina
Keyword(s):  
Amniotic Fluid ◽  
Metal Ions ◽  
Fetal Growth ◽  
Growth Retardation ◽  
Copper Content ◽  
Developmental Disorders ◽  
Normal Pregnancy ◽  
Fetal Growth Retardation ◽  
Magnesium Ions ◽  
Free Metal

The levels of zinc, copper, iron, and magnesium ions, and some of their binding proteins have been investigated in an amniotic fluid under the fetal growth retardation (FGR). FGR, developed under conditions of placental insufficiency, is characterized by a decrease in the content of zinc, iron, and magnesium ions and by an increase in the copper content in the amniotic fluid in the II and III trimesters of pregnancy. During these trimesters the levels of ceruloplasmin, ferritin, and Ca2+,Mg2+-ATPase were lower in FGR, while the level of zinc-a-2-glycoprotein was higher than during the same periods of normal pregnancy. Changes in the parameters studied in the amniotic fluid were associated with developmental disorders of the newborns. These changes obviously have a pathogenetic importance in the development of FGR, and the levels of metal ions and their ratio in the amniotic fluid can be used as markers of the pre- and postnatal pathology.

scholarly journals The Role of HLAC and NK Cells in Fetal Growth Restriction

2017 ◽  
pp. 142
Author(s):  
Sri Sulistyawati ◽  
Didon M Trimulya ◽  
Supriyadi H Respati ◽  
Soetrisno Soetrisno
Keyword(s):  
Nk Cells ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Nk Cell ◽  
Normal Pregnancy ◽  
Growth Restriction ◽  
Immunohistochemical Method ◽  
Cross Sectional ◽  
The Mean

Objective: To determine the role of HLA-C and NK cell expressions in fetal growth restriction (FGR). Methods: A cross sectional study design was used. This study was conducted at the Obstetrics and Gynecology Department of Dr. Moewardi General Hospital, Surakarta, its affiliated hospitals, and at the Pathological Anatomy Laboratory of the Faculty of Medicine, University of Sebelas Maret Surakarta. A total of 40 samples were included in this study. The samples consisted of 20 normal pregnancies and 20 pregnancies with FGR. HLA-C expression in the trophoblast and NK cells in decidua of the subjects who met the inclusion and exclusion criteria were examined using immunohistochemical method and statistical analysis with T test. Results: The mean expression of HLA-C in the trophoblast in the pregnant group with FGR was 9.021.30, normal pregnancy was 7.96 ± 0.97, p=0.01 (p<0.05). The mean expression of NK cells in decidua of pregnancy with FGR was 10.59 ± 2.11, normal pregnancy was 0.91 ± 8.18, with p=0.00 (p<0.05). Conclusion: The expressions of HLA-C in trophoblast and NK cells in decidua of pregnancy with FGR were higher compared with those of normal pregnancy. [Indones J Obstet Gynecol 2017; 5-3: 142-148] Keywords: fetal growth restriction, HLA-C, NK cells

Cell-specific metallothionein gene expression in mouse decidua and placentae

Development ◽  
1989 ◽  
Vol 107 (3) ◽  
pp. 611-621 ◽  
Author(s):  
S.K. De ◽  
M.T. McMaster ◽  
S.K. Dey ◽  
G.K. Andrews
Keyword(s):  
Gene Expression ◽  
In Situ Hybridization ◽  
Embryo Implantation ◽  
Normal Pregnancy ◽  
Mrna Levels ◽  
Metallothionein Gene ◽  
Visceral Yolk Sac ◽  
Rna In Situ Hybridization ◽  
Low Levels

Oligodeoxyribonucleotide excess solution hybridization, Northern blot and in situ hybridization were used to analyze metallothionein gene expression in mouse decidua and placentae during gestation. Metallothionein (MT) -I and -II mRNA levels were constitutively elevated, 11- and 13-fold, respectively, relative to the adult liver, in the deciduum (D8), and decreased coordinately about 6-fold during the period of development when the deciduum is replaced by the developing placenta (D10-16). Coincident with this decline, levels of MT mRNA increased dramatically in the visceral yolk sac endoderm. In situ hybridization established that MT-I mRNA was present at low levels in the uterine luminal epithelium (D4), but was elevated at the site of embryo implantation exclusively in the primary decidual zone by D5, and then in the secondary decidual zone (D6-8). Although low levels of MT mRNA were detected in total placental RNA, in situ hybridization revealed constitutively high levels in the outer placental spongiotrophoblasts. Analysis of pulse-labeled proteins from decidua and placentae established that these tissues are active in the synthesis of MT. The constitutively high levels of MT mRNA in decidua were only slightly elevated following injection of cadmium (Cd) and/or zinc (Zn), whereas in placentae they increased several-fold. MT mRNA levels were equally high in decidua and experimentally induced deciduomata (D8) which establishes that decidual MT gene expression is not dependent on the presence of the embryo or some embryo-derived factor. Although the functional role of MT during development is speculative, these results establish the concept that, from the time of implantation to late in gestation, the mouse embryo is surrounded by cells, interposed between the maternal and embryonic environments, which actively express the MT genes. This suggests that MT plays an important role in the establishment and maintenance of normal pregnancy.

Pregnancy and obstetric complications in women with autoimmune diseases

2021 ◽  
pp. 125-142
Author(s):  
D. Ware Branch
Keyword(s):  
Menstrual Cycle ◽  
Autoimmune Diseases ◽  
Chorionic Gonadotropin ◽  
Early Pregnancy ◽  
Human Chorionic Gonadotropin ◽  
Normal Pregnancy ◽  
Obstetric Complications ◽  
Optimal Management ◽  
Foetal Development ◽  
Rheumatic Conditions

For most women, pregnancy is suspected when the symptoms of early pregnancy develop—these include breast soreness or tenderness, fatigue, nausea, and missed menses. Human chorionic gonadotropin (hCG) is first detectable using sensitive tests in the urine and blood of pregnant women 8–10 days after conception (day 22–24 of a 28-day menstrual cycle). Concentrations of hCG rise rapidly in early pregnancy, peak at 9–10 weeks, and decline thereafter to a nadir at 20 weeks. Understanding embryo-foetal development and maternal physiological accommodation to pregnancy is required for the optimal management of pregnancy in women with autoimmune diseases. This chapter reviews the important developmental and physiologic aspects of normal pregnancy and both common and unique obstetric complications associated with selected rheumatic conditions.

Sign in / Sign up

Export Citation Format

Share Document